SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-034961
Filing Date
2023-10-02
Accepted
2023-10-02 08:45:26
Documents
14
Period of Report
2023-09-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48467
2 ex99-1.htm EX-99.1 25984
3 ex99-2.htm EX-99.2 16606
  Complete submission text file 0001493152-23-034961.txt   269525

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rspi-20230926.xsd EX-101.SCH 3018
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rspi-20230926_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rspi-20230926_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3040
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 231298035
SIC: 2834 Pharmaceutical Preparations